says Andrew Hurst, a spokesman for the fund, which is based in Geneva, Switzerland. The pledge marks a 20% increase on the $9.7 billion raised for the period 2008-10 at its last fundraising meeting in Berlin in 2007. Given today's economic climate, the outcome could have been far worse, he says.
The bad news is that the fund has not raised enough cash to reduce disease burdens among the poor by 2015, to levels to which countries have committed in the UN Millennium Development Goals. In the run-up to the meeting, the fund had estimated that it needed $20 billion to start making serious progress on this task, whereas $13 billion would buy only minimal burden reductions (see 'The human cost').
The poor funding outcome starkly highlights a chronic structural weakness of the Global Fund: its narrow base of donors. Just a couple of dozen countries donated, and a mere seven countries gave more than $100 million -the United States, France, Germany, Japan, Canada, Norway and Australia. Three other countries traditionally supportive of the fund -the United Kingdom, the Netherlands and Sweden -were unable to officially pledge at the meeting because of the timing of national budgets, but are likely to commit sums that will allow the Global Fund to reach its $13-billion lower target. Yet dozens of rich countries, including Italy, Spain and Saudi Arabia, gave nothing. The fund is seeking to persuade more nations to pledge, says Hurst, but admits that "we still have some way to go".
For the first time in its history, the fund will now be forced to reject otherwise-solid new proposals from recipient countries, and trim others. "Today marks a sad turning point in the fight against AIDS, TB and malaria, as world leaders have officially underfinanced the Global Fund," Peach hopes that the first phase of the cancer programme will pave the way for expanding genetic testing to more patients and other conditions, such as diabetes, AIDS and even psychiatric disorders. Cancer offers a good testing ground for personalized medicine, because numerous targeted therapies already exist, but "there's no reason why this should be restricted to cancer", says Peach.
Fabrice André, who runs a similar cancer diagnostic programme that has so far been offered to about 100 patients at the Gustave Roussy Institute in Villejuif, France, says the NHS programme could point the way to implementing personalized medicine across an entire population. "It can really change the landscape of how molecular testing is being done for cancer, " he says. "If they succeed, then it's going to be a major step forward. " ■
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Global disease fund hit by cash crisis
Pledges fall short for fight against AIDS, TB and malaria.
THE HUMAN COST
Estimating the e ect of di erent funding scenarios for 2011-13 shows that although US$20 billion would allow a signi cant scale-up of activities, $13 billion yields far less progress towards internationally agreed targets for 2015. in focus nEWs
